Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Mach7 Technologies ( (AU:M7T) ).
Mach7 Technologies reported a significant quarter with key developments including the initial deployment of its solutions in the U.S. Veterans Health Administration’s National Teleradiology Program. This quarter marked a strategic reset with leadership changes and a focus on high-value enterprise opportunities in Asia and the Middle East. The company achieved a CARR of A$29.6M and an ARR run rate of A$23.5M, highlighting its financial stability with no debt and cash reserves of A$18.9M. The company is poised for growth with a streamlined leadership team and expanded operations in Malaysia, aiming for sustained momentum and a rebound in the latter half of FY26.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
More about Mach7 Technologies
Mach7 Technologies Limited is a company specializing in innovative medical imaging software solutions. It focuses on providing enterprise image archiving and diagnostic viewing services, with a market focus that includes healthcare sectors such as telestroke and mammography.
Average Trading Volume: 226,580
Technical Sentiment Signal: Sell
Current Market Cap: A$66.97M
Learn more about M7T stock on TipRanks’ Stock Analysis page.